Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Galderma’s investigational prurigo nodularis drug hits Phase II endpoint

pharmatimesMarch 10, 2020

Tag: Galderma , prurigo nodularis , PN

PharmaSources Customer Service